Drug Profile
KB 001 A
Alternative Names: Anti-PcrV mAb fragment; KB 001; KB-001ALatest Information Update: 08 Aug 2017
Price :
$50
*
At a glance
- Originator KaloBios Pharmaceuticals
- Class Antibacterials; Antibodies; Monoclonal antibodies
- Mechanism of Action PcrV inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Pseudomonal infections; Ventilator associated pneumonia
Most Recent Events
- 07 Aug 2017 KaloBios Pharmaceuticals is now called Humanigen
- 30 Jun 2015 Discontinued - Phase-I for Ventilator-associated-pneumonia (Prevention) and Pseudomonal infections (Prevention) in USA (IV)
- 30 Jun 2015 Discontinued - Phase-I/II for Ventilator-associated-pneumonia (Prevention) and Pseudomonal infections (Prevention) in France (IV)